Phase 1 trial of TEAD inhibitor VT3989 : Trial status and future directions

Time: 2:45 pm
day: Conference Day One

Details:

• Exploring Phase 1 clinical data of VT3989
• Detailing translation of preclinical data to clinical results
• Reviewing tuture development directions

Speakers: